Pharma Giants Battle Over Weight-Loss Drugs While Earnings and FDA Approvals Drive Market Trends

This material discusses recent developments in the pharmaceutical industry, including Eli Lilly's competition with Novo Nordisk in the weight-loss market, profit increases for Abbott India and Zimmer Biomet, Roche considering selling Flatiron Health, the Philippines' emergency procurement of ASF vaccines, and FDA approvals for new treatments.

The pharmaceutical sector is buzzing with key developments as Eli Lilly's Zepbound intensifies its battle against Novo Nordisk's Wegovy in the U.S. weight-loss market. Lilly's market share for Zepbound has swiftly climbed to approximately 40% since its launch, according to recent data.

In other news, Abbott India has reported a significant 13% rise in first-quarter profit, driven by increased sales and price adjustments. Meanwhile, Swiss pharma giant Roche is contemplating selling its cancer data startup, Flatiron Health, and the Philippines is seeking emergency swine flu vaccines amid an outbreak.

Additionally, Novo Nordisk has faced a rare setback, revising its profit outlook and seeing a dip in share prices due to underwhelming Wegovy sales. On a positive note, Zimmer Biomet and Servier Pharmaceuticals have reported strong demand and FDA approvals, respectively.

(With inputs from agencies.)